Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: thiotepa
Drug: paclitaxel
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2015-08-04

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 72

Registration Number: NCT00004092

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Banner Good Samaritan Medical Center, Phoenix, Arizona, United States

Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-26

Lead Sponsor: Societe Internationale d'Oncologie Pediatrique

Target Recruit Count: 65

Registration Number: NCT00004224

Locations: 🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇸🇪
Ostra Sjukhuset, Gothenburg, Sweden
🇪🇸
Hospital Des Cruces, Vizcaya, Spain

and more 4 locations

Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor

Phase 3

Completed

Conditions: Untreated Childhood Medulloblastoma
Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor

Interventions: Drug: cisplatin
Drug: cyclophosphamide
Drug: vincristine sulfate
Drug: etoposide
Procedure: therapeutic conventional surgery
Radiation: 3-dimensional conformal radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-09

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 82

Registration Number: NCT00006461

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery

Phase 3

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-07

Lead Sponsor: Cancer Research Campaign Clinical Trials Centre

Registration Number: NCT00039546

Locations: 🇬🇧
Glan Clywd District General Hospital, Rhyl, Denbighshire, United Kingdom
🇬🇧
Morriston Hospital NHS Trust, West Glamorgen, United Kingdom
🇬🇧
Singleton Hospital, Swansea, United Kingdom

and more 43 locations

Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma

Phase 2

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-07

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00024193

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Combination Chemotherapy in Treating Women With Stage III Breast Cancer

Phase 3

Suspended

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-02

Lead Sponsor: Grupo Oncologico Cooperativo del Sur

Registration Number: NCT00002696

Locations: 🇦🇷
Unidad Oncologica Del Comahue, Neuquen, Argentina
🇦🇷
Centro De Oncologia y Terapia Radiante, Santa Rosa, La Pampa, Argentina
🇦🇷
Policlinica Privada Instituto De Medicina Nuclear, Bahia Blanca, Buenos Aires, Argentina

and more 3 locations

Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-02

Lead Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH

Registration Number: NCT00017225

Locations: 🇩🇪
Carl - Thiem - Klinkum Cottbus, Cottbus, Germany
🇩🇪
Klinikum Lippe - Detmold, Detmold, Germany
🇩🇪
Praxis am Evangelischen Krankenhaus Bethanien, Iserlohn, Germany

and more 85 locations

Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney

Phase 2

Conditions: Kidney Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 75

Registration Number: NCT00025103

Locations: 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
🇬🇧
Great Ormond Street Hospital for Children, London, England, United Kingdom
🇬🇧
Southampton General Hospital, Southampton, England, United Kingdom

and more 17 locations

Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 50

Registration Number: NCT00025077

Locations: 🇬🇧
Great Ormond Street Hospital for Children NHS Trust, London, England, United Kingdom
🇬🇧
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧
Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom

and more 17 locations

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer
Melanoma (Skin)

Interventions: Biological: filgrastim
Biological: therapeutic allogeneic lymphocytes
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2014-03-07

Lead Sponsor: University of Chicago

Target Recruit Count: 19

Registration Number: NCT00004135

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy